{"title": "National Pharmaceutical Regulatory Agency (NPRA) - Home", "author": null, "url": "https://npra.gov.my/index.php/en/", "hostname": "npra.gov.my", "description": "National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Malaysia Drug Control Authority", "sitename": "National Pharmaceutical Regulatory Agency (NPRA)", "date": "2023-08-15", "cleaned_text": "Reactions after Consumption of Oral Aloe FOR REGISTERED PRODUCTS](/index.php/en/guidelines-for-compliance-licensing/1527216-guideline-on-application-of-manufacturer-s-import-and-wholesaler-s-licenses-for-registered-products.html) Fatal Respiratory Failure and Sepsis/Septic Shock in Patients with Type 1 Hepatorenal Syndrome (Type 1 HRS)](/index.php/en/component/content/article/449-english/safety-alerts-main/safety-alerts-2023/1527494-terlipressin-glypressin-serious-or-fatal-respiratory-failure-and-sepsis-septic-shock-in-patients-with-type-1-hepatorenal-syndrome-type-1-hrs.html?Itemid=1391) [Keperluan Suppositories to Fever in Children: Potential Risk of Acute Necrotising Encephalopathy of Childhood (ANEC)](/index.php/en/component/content/article/449-english/safety-alerts-main/safety-alerts-2023/1527481-off-label-use-of-diclofenac-suppositories-to-treat-fever-in-children-potential-risk-of-acute-necrotising-encephalopathy-of-childhood-anec.html?Itemid=1391) [An Analysis of Deficiencies Observed During On-Site Good Manufacturing Practice (GMP) Inspections of Local and Foreign Manufacturing Premise of Medicinal Registered Products in the Year 2022](/index.php/en/component/content/article/436-english/announcement-main/announcement-2023/1527480-an-analysis-of-deficiencies-observed-during-on-site-good-manufacturing-practice-gmp-inspections-of-local-and-foreign-manufacturing-premise-of-medicinal-registered-products-in-the-year-2023.html?Itemid=1391) [Kenyataan Media KPK 23 Supplements (HS) Manufacturers](/index.php/en/guidelines-for-compliance-licensing/1527475-guidance-document-verification-for-traditional-medicines-tm-health-supplements-hs-manufacturers.html) [Pemakluman Pertukaran Tempat Penganjuran National Regulatory Conference (NRC) 2023 Drug Registration Guidance Document Fourth Revision January 2023](/index.php/en/directive-general/1527460-direktif-untuk-penggunaan-drug-registration-guidance-document-drgd-third-edition-fourth-revision-january-2023.html) [Kenyataan Media the Acceptance Criteria for Quantification by Input (QBI) of Active Ingredients Claimed on Label of Traditional Medicine and Health Supplement (TMHS) Products](/index.php/en/directive-general/1527424-direktif-berkenaan-pelaksanaan-garis-panduan-guidance-on-the-acceptance-criteria-for-quantification-by-input-qbi-of-active-ingredients-claimed-on-label-of-traditional-medicine-and-health-supplement-tmhs-products.html) Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks)](/index.php/en/component/content/article/444-english/safety-alerts-main/safety-alerts-2022/1527402-brolucizumab-pagenax-risk-of-intraocular-inflammation-including-retinal-vasculitis-and-or-retinal-vascular-occlusion-updated-recommendations-to-minimise-the-known-risks.html?Itemid=1391) [Alectinib (Alecensa\u00ae): Risk of Haemolytic Anaemia (New Warning and Precaution and Dose Modification Guidance)](/index.php/en/component/content/article/444-english/safety-alerts-main/safety-alerts-2022/1527401-alectinib-alecensa-risk-of-haemolytic-new-warning-and-precaution-and-dose-modification-guidance.html?Itemid=1391) Media KPK for Traditional Medicines & Health Supplements Manufacturers](/index.php/en/guidelines-for-compliance-licensing/1527385-guidance-document-product-quality-review-pqr-for-traditional-medicines-health-supplements-manufacturers.html) [Update on Guidance Notes for Active Pharmaceutical Ingredients (API) Information for Product Registration - Version 6.1 (July 2022)](/index.php/en/component/content/article/427-english/announcement-main/announcement-2022/1527383-update-on-guidance-notes-for-active-pharmaceutical-ingredients-api-information-for-product-registration-version-6-1-july-2022.html?Itemid=1391) [Direktif untuk penggunaan Drug Registration Guidance Document How the Analytical Method Validation Report in Quest 3+ System Under Section E12 & E13](/index.php/en/component/content/article/225-english/1527363-guide-on-how-to-upload-the-analytical-method-validation-report-in-quest-3-system-under-section-e12-e13.html?Itemid=1391) [Mavenclad\u00ae (Cladribine): Risk of Serious Liver Injury and New Guidance Document (DRGD)](/index.php/en/directive-general/1527354-pekeliling-berkenaan-pengemaskinian-status-bahan-aktif-magnolia-officinalis-dalam-drug-registration-guidance-document-drgd.html) [Guidelines on Conditional Registration for New Chemical Entities and Biologics in Malaysia - 2nd Edition - [Refund Procedure Involving Online Payment Made Via National Pharmaceutical Regulatory Agency QUEST3+ System](/index.php/en/component/content/article/427-english/announcement-main/announcement-2022/1527341-refund-procedure-involving-online-payment-made-via-national-pharmaceutical-regulatory-agency-quest3-system.html?Itemid=1391) [Kenyataan Media (GVP) Inspection on Pharmaceutical Product Registration Holders (PRHs)](/index.php/en/component/content/article/82-english/announcement-main/1527329-voluntary-good-pharmacovigilance-practices-gvp-inspection-on-pharmaceutical-product-registration-holders-prhs.html?Itemid=1391) [Malaysian Guidance Document on Voluntary Good Pharmacovigilance Practices (GVP) Inspection (1st Edition, March 2022)](/index.php/en/guideline-for-pharmacovigilance/1527328-malaysian-guidance-document-on-good-pharmacovigilance-practices-gvp-inspection.html) [Kenyataan Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia](/index.php/en/guideline-bio/1527314-guidance-document-and-guidelines-for-registration-of-cell-and-gene-therapy-products-cgtps-in-malaysia-2.html) [Kenyataan of BE Studies Conducted at the BE Centre Micro Therapeutic Labs Following Inspection Findings by The European Medicines Agency (EMA)](/index.php/en/component/content/article/427-english/announcement-main/announcement-2022/1527306-rejection-of-be-studies-conducted-at-the-be-centre-micro-therapeutic-labs-following-inspection-findings-by-the-european-medicines-agency-ema.html?Itemid=1391) [Direktif untuk penggunaan Drug Registration Guidance Document Second Revision January 2022](/index.php/en/component/content/article/82-english/announcement-main/1527301-direktif-untuk-penggunaan-drug-registration-guidance-document-drgd-third-edition-second-revision-january-2022.html?Itemid=1391) [Direktif untuk penggunaan Drug Registration Guidance Document (DRGD) Third Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]](/index.php/en/component/content/article/444-english/safety-alerts-main/safety-alerts-2022/1527287-janus-kinase-jak-inhibitors-in-rheumatoid-arthritis-patients-risk-of-major-adverse-cardiovascular-events-mace-and-malignancies-excluding-non-melanoma-skin-cancer-nmsc.html?Itemid=1391) [Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]](/index.php/en/component/content/article/426-english/safety-alerts-main/safety-alerts-2021/1527288-janus-kinase-jak-inhibitors-in-rheumatoid-arthritis-patients-risk-of-major-adverse-cardiovascular-events-mace-and-malignancies-excluding-non-melanoma-skin-cancer-nmsc-2.html?Itemid=1391) [Sulfamethoxazole & Lab Susulan Penemuan Pemeriksaan United States Food and Drug Administration (US FDA)](/index.php/en/component/content/article/429-english/malay/announcement-main/pengumuman-2021/1527269-penolakan-kajian-bioekuivalens-be-yang-dijalankan-oleh-pusat-kajian-be-synchron-research-services-dan-panexcell-clinical-lab-susulan-penemuan-pemeriksaan-united-states-food-and-drug-administration-us-fda.html?Itemid=1391) [Rejection of Bioequivalence (BE) Studies Conducted at The BE Centres Synchron Research Services and Panexcell Clinical Lab Following Inspection Findings by The United States Food and Drug Administration (US FDA)](/index.php/en/component/content/article/425-english/announcement-main/announcement-2021/1527270-rejection-of-bioequivalence-be-studies-conducted-at-the-be-centres-synchron-research-services-and-panexcell-clinical-lab-following-inspection-findings-by-the-united-states-food-and-drug-administration-us-fda-translated-version.html?Itemid=1391) [Pembatalan Document For Preparation Of Good Manufacturing Practice (GMP) Inspections On Traditional Medicines, Health Supplements And Cosmetics (1st CONTROL OF COSMETIC PRODUCTS IN MALAYSIA](/index.php/en/directives-cosmetic-products/1527249-pekeliling-bil-2-2021-makluman-berkenaan-status-kemaskini-bahan-bahan-dalam-annex-pada-guidelines-for-control-of-cosmetic-products-in-malaysia.html) [Guideline for Application of Private Laboratories Complying to NPRA Natural Preparation Of Good Manufacturing Practice (GMP) Inspections On Traditional Medicines, Health Supplements and (VEGF) inhibitors for systemic use (except application on eyes): Risk of artery dissections and aneurysms](/index.php/en/component/content/article/426-english/safety-alerts-main/safety-alerts-2021/1527213-vascular-endothelial-growth-factor-vegf-inhibitors-for-systemic-use-except-application-on-eyes-risk-of-artery-dissections-and-aneurysms.html?Itemid=1391) [Mirtazapine: Risks of (i) Amnesia and (ii) Drug Reaction Eosinophilia and in pregnant women and in women of childbearing potential who are not using effective contraception](/index.php/en/component/content/article/419-english/safety-alerts-main/safety-alerts-2020/1527152-gilenya-fingolimod-new-contraindication-in-pregnant-women-and-in-women-of-childbearing-potential-who-are-not-using-effective-contraception.html?Itemid=1391) [Parenteral nutrition containing amino acids and/or lipids: Risk of toxic degradations of ingredients when exposed to light, which may lead to adverse outcomes in paediatric patients less than 2 years for Veterinary Products](/index.php/en/component/content/article/40-english/circulars/1527134-pekeliling-berkenaan-pelaksanaan-guidelines-on-abridged-registration-pathway-for-veterinary-products.html?Itemid=1391) [e-ENGAGEMENT SESSION: PHASES OF IMPLEMENTATION OF ROUTINE GOOD DISTRIBUTION PRACTICE (GDP) INSPECTION ON IMPORTER AND WHOLESALER OF COLD CHAIN PRODUCT / TIME & TEMPERATURE SENSITIVE Control Order In NPRA](/index.php/en/component/content/article/418-english/announcement-main/announcement-2020/1527074-perlaksanaan-perintah-kawalan-pergerakan-di-premis-npra.html?Itemid=1391) [Kyprolis\u00ae (carfilzomib): (i) Risk of progressive multifocal leukoencephalopathy DI PERINGKAT (i) Risk of congenital malformation in neonates and neurodevelopmental problems in children exposed to sodium valproate during pregnancy; (ii) Additional educational material for healthcare in Administrative Procedure for Section S Revision for Registered Products (Non Anti-Infectives) with the Expiration of Registration Starting 1 January 2020](/index.php/en/component/content/article/418-english/announcement-main/announcement-2020/1527053-change-in-administrative-procedure-for-section-s-revision-for-registered-products-non-anti-infectives-with-the-expiration-of-registration-starting-1-january-2020.html?Itemid=1391) [Kenyataan Akhbar KPK risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/1527034-feburic-febuxostat-increased-risk-of-cardiovascular-death-and-all-cause-mortality-in-patients-treated-with-febuxostat-in-the-cares-study.html?Itemid=1391) [Traditional, Health Supplement & Cosmetics Manufacturer: Regulatory Act upon Manufacturer with Unpaid GMP Inspection for use in children aged below 2 years and pregnant or breastfeeding women](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/1527023-smecta-dioctahedral-smectite-not-recommended-for-use-in-children-aged-below-2-years-and-pregnant-or-breastfeeding-women.html?Itemid=1391) GUIDELINES FOR CONTROL OF COSMETIC with boosted antiviral Human Immunodeficiency Virus (HIV) therapy leading to insufficient inhibition of platelet aggregation](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/1527006-clopidogrel-interaction-with-boosted-antiviral-human-immunodeficiency-virus-hiv-therapy-leading-to-insufficient-inhibition-of-platelet-aggregation.html?Itemid=1391) [LEMTRADA\u00ae (alemtuzumab): (i) Risk of autoimmune hepatitis (ii) Other serious reactions temporally associated with alemtuzumab infusion (iii) Haemophagocytic lymphohistiocytosis](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/1527005-lemtrada-alemtuzumab-i-risk-of-autoimmune-hepatitis-ii-other-serious-reactions-temporally-associated-with-alemtuzumab-infusion-iii-haemophagocytic-lymphohistiocytosis.html?Itemid=1391) [Reminder: Implementation of Regulatory Control of Active Pharmaceutical Ingredients (API) For Registered Products with Registration Expiration Starting 1 January side effects (tendinitis, tendon side effects (tendinitis, tendon peripheral neuropathy & central nervous system/ neuropsychiatric effects)](/index.php/en/directive-general/2132-direktif-untuk-semua-produk-yang-mengandungi-antibiotik-kumpulan-fluoroquinolone-sediaan-oral-dan-injeksi-pengemaskinian-sisip-bungkusan-dan-risalah-maklumat-ubat-untuk-pengguna-rimup-dengan-maklumat-keselamatan-berikut-a-membatalkan-dan-menghadkan-indikasi-antibiotik-kumpulan-fluoroquinolone-b-amaran-berkaitan-disabling-and-potentially-permanent-side-effects-tendinitis-tendon-rupture-peripheral-n.html) [Biowaiver Considerations Based Unavailability/Inaccessibility of Comparator Product and Other Considerations](/index.php/en/biowaivers.html) [Imovane\u00ae (zopiclone): New restriction of the indication and additional warnings on abuse and dependence](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/2109-imovane-zopiclone-new-restriction-of-the-indication-and-additional-warnings-on-abuse-and-dependence.html?Itemid=1391) [Update of Annex 1: Requirements for Active Pharmaceutical Ingredient (API) Information during Section Implementation Of Bioequivalence (BE) Study Requirements For New Drug Products Containing Scheduled Poison](/index.php/en/component/content/article/410-english/announcement-main/announcement-2019/2087-public-consultation-on-implementation-of-bioequivalence-be-study-requirements-for-new-drug-products-containing-scheduled-poison.html?Itemid=1391) [Kenyataan Akhbar KPK 29 Risk of birth defects and neonatal disorders in case of exposure during pregnancy; (ii) Risk of pancreatitis](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/2082-carbimazole-and-methimazole-thiamazole-i-risk-of-birth-defects-and-neonatal-disorders-in-case-of-exposure-during-pregnancy-ii-risk-of-pancreatitis.html?Itemid=1391) [Tapentadol: Risk of seizures and reports of serotonin syndrome when co-administered with other drugs](/index.php/en/component/content/article/414-english/safety-alerts-main/safety-alerts-2019/2080-tapentadol-risk-of-seizures-and-reports-of-serotonin-syndrome-when-co-administered-with-other-drugswith-other-drugs.html?Itemid=1391) [Direktif untuk melaksanakan of Regulatory Control of Active Pharmaceutical Ingredients (API) For Registered Products with Registration Expiration Starting 1 January 2020](/index.php/en/component/content/article/410-english/announcement-main/announcement-2019/2068-reminder-implementation-of-regulatory-control-on-active-pharmaceutical-ingredients-api-for-registered-products-with-registration-expiration-starting-1-january-2020.html?Itemid=1391) [Kenyataan Akhbar KPK 18 Mac 2019 [Apixaban: Drug interaction between apixaban and/or Serotonin and leading to increased risk of bleeding](/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1757-apixaban-drug-interaction-between-apixaban-and-selective-serotonin-reuptake-inhibitors-snri-and-or-serotonin-and-noradrenaline-reuptake-inhibitors-snri-leading-to-increased-risk-of-bleeding.html?Itemid=1391) [NRC 2018 Post Conference Seminar on WHO Good Practices for Desk Assessment for Compliance with GMP / GCP /GLP](/index.php/en/component/content/article/212-english/announcement-main/announcement-2018/1615-nrc-2018-post-conference-seminar-on-who-good-practices-for-desk-assessment-for-compliance-with-gmp-gcp-glp.html?Itemid=1391) [2018 Education Seminar Series: Analysis of Findings from GMP Inspections of Pharmaceutical Manufacturers & Introduction to 'Guidance Document of Pre-Approval GMP Inspection](/index.php/en/component/content/article/212-english/announcement-main/announcement-2018/1617-2018-education-seminar-series-analysis-of-findings-from-gmp-inspections-of-pharmaceutical-manufacturers-introduction-to-guidance-document-of-pre-approval-gmp-inspection.html?Itemid=1391) [Submission Of Bioequvalence (BE) Study Reports For Registered Generic Products In The Form Of Effervescent, Dispersible, Orodispersible, Sublingual, [Section E : Supplementary Documentation (And Particulars Of Product Owner, Manufacturer, Importer And Other Questions (FAQS) About Foreign Gmp Inspection On Manufacturers Of Pharmaceutical Products By National Pharmaceutical Regulatory Agency (NPRA)](/index.php/en/component/content/article/2-english/uncategorised/1625-frequently-asked-questions-faqs-about-foreign-gmp-inspection-on-manufacturers-of-pharmaceutical-products-by-national-pharmaceutical-regulatory-agency-npra.html?Itemid=1391) [Domperidone and clarithromycin: Drug interaction leading to increased Pada Guidelines Of Cosmetic Products In Malaysia (26 Julai 2018)](/index.php/en/directives-cosmetic-products/1636-pekeliling-bil-3-2018-makluman-berkenaan-status-kemaskini-bahan-bahan-dalam-annex-pada-guidelines-for-control-of-cosmetic-products-in-malaysia-26-julai-2018.html) [General Conditions For Registration Of Drug Products Under The Control Of Drugs And Cosmetics Regulations 1984](/index.php/en/general-conditions-for-registration-of-drug-products-under-the-control-of-drugs-and-cosmetics-regulations-1984.html) Registration Guidance Document registration of generic products, PRH shall provide patent declarations as below: i) PRH shall comply with all legal provisions in Malaysia; ii) The government/ authority is not liable for any offence committed by the PRH Cutaneous Adverse Reactions (SCARs)](/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1646-carbocisteine-and-acetylcysteine-anaphylactic-anaphylactoid-reactions-and-severe-cutaneous-adverse-reactions-scars.html?Itemid=1391) [Drug interaction of oral contraceptives containing ethinylestradiol with the direct-acting antiviral combinations of paritaprevir, ritonavir and ombitasvir with or without dasabuvir](/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1647-drug-interaction-of-oral-contraceptives-containing-ethinylestradiol-with-the-direct-acting-antiviral-combinations-of-paritaprevir-ritonavir-and-ombitasvir-with-or-without-dasabuvir.html?Itemid=1391) [Amoxicillin-containing products: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and strengthening the risk of Severe Cutaneous Adverse when co-administered with valproate](/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1652-propofol-and-sodium-valproate-risk-of-increased-propofol-blood-level-when-co-administered-with-valproate.html?Itemid=1391) [Direktif untuk melaksanakan guidelines on conditional acetate): Women taking Esmya\u00ae for uterine fibroids to have regular liver tests while safety review is ongoing; do not initiate treatment in new patients or those who have completed a previous treatment following evidence of gadolinium deposits in the brain after magnetic resonance imaging (MRI) body scans](/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1283-gadolinium-based-contrast-agents-suspension-restriction-of-use-following-evidence-of-gadolinium-deposits-in-the-brain-after-magnetic-resonance-imaging-mri-body-scans.html?Itemid=1391) [Check Addresses Registered Under Company To Ensure There Is No Duplicated Address Or severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic Cosmetic (7 Februari 2018)](/index.php/en/component/content/article/40-english/circulars/1263-makluman-berkenaan-status-kemaskini-bahan-bahan-dalam-annexes-pada-guidelines-for-control-of-cosmetic-products-in-malaysia-7-februari-2018.html?Itemid=1391) Pada Notes on Annex 1: Management of Time and Temperature Sensitive Products (TTSP) of Guideline on Good Distribution Practice](/index.php/en/component/content/article/138-english/guidelines-general/1535-supplementary-notes-on-annex-1-management-of-time-and-temperature-sensitive-products-ttsp-of-guideline-on-good-distribution-practice.html?Itemid=1391) [Xofigo\u00ae (radium-223 dichloride): Important Safety Information Update Regarding Increased Incidence of Deaths and Fractures in a Randomized Clinical Trial with Xofigo\u00ae used in Combination with and Observed When Used in Non-approved Combination Treatments or Outside the Approved Indications; Monitor for Opportunistic Infections and Hepatitis MALAYSIA (4 Julai 2017)](/index.php/en/directives-cosmetic-products/1938-pekeliling-untuk-memaklumkan-status-kemaskini-bahan-bahan-dalam-annexes-pada-guidelines-for-control-of-cosmetic-products-in-malaysia-4-julai-2017.html) [Keytruda\u00ae (pembrolizumab): Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs), December 2015 dan Good Tissue Practice Guideline, 2nd [Direktif Untuk Menguatkuasakan Penggunaan Guideline Cosmetic Products In Malaysia- 1st Revision, February 2017 (3 Mac 2017)](/index.php/en/directives-cosmetic-products/1144-pekeliling-untuk-memaklumkan-penerbitan-edisi-terkini-garis-panduan-kosmetik-iaitu-guideline-for-control-of-cosmetic-products-in-malaysia-1st-revision-february-2017-3-mac-2017.html) [Pomalyst\u00ae (pomalidomide): New important advice- Hepatitis B Virus status to be established before initiating treatment with pomalidomide](/index.php/en/component/content/article/74-english/safety-alerts-main/safety-alert-2017/1143-pomalyst-pomalidomide-new-important-advice-hepatitis-b-virus-status-to-be-established-before-initiating-treatment-with-pomalidomide.html?Itemid=1391) [Direktif Keperluan Sijil Analisa Produk OF COSMETIC PRODUCTS IN MALAYSIA (27 Jan 2017)](/index.php/en/directives-cosmetic-products/1939-pekeliling-untuk-memaklumkan-status-kemaskini-bahan-bahan-dalam-annexes-pada-guidelines-for-control-of-cosmetic-products-in-malaysia-27-jan-2017.html) [Kenyataan Creative Health Resources (CHR) Creative Nutrition'](/index.php/en/component/content/article/39-english/press-release/press-release-2016/1110-kenyataan-akhbar-kpk-16-disember-2016-amaran-kepada-orang-awam-berkenaan-pengambilan-produk-tidak-berdaftar-creative-health-resources-chr-creative-herbs-dan-creative-health-resources-chr-creative-nutrition.html?Itemid=1391) [Seminar: ASEAN Common Technical for Malaysian Submission](/index.php/en/component/content/article/36-english/announcement-main/announcement-2016/1095-seminar-asean-common-technical-dossier-actd-preparation-generic-products-for-malaysian-submission.html?Itemid=1391) [Implanon NXT\u00ae (etonogestrel): Implants have been found rarely in the vasculature and lung. An update on possible risks and complications regarding insertion, localisation, removal and migration](/index.php/en/component/content/article/58-english/safety-alerts-main/safety-alert-2016/1094-implanon-nxt-etonogestrel-implants-have-been-found-rarely-in-the-vasculature-and-lung-an-update-on-possible-risks-and-complications-regarding-insertion-localisation-removal-and-migration.html?Itemid=1391) [Invokana\u00ae (canagliflozin): Advice on the risk of lower limb amputation (primarily of the toe) during treatment with canagliflozin-containing medicines](/index.php/en/component/content/article/58-english/safety-alerts-main/safety-alert-2016/1093-invokana-canagliflozin-advice-on-the-risk-of-lower-limb-amputation-primarily-of-the-toe-during-treatment-with-canagliflozin-containing-medicines.html?Itemid=1391) now restricted patients whose tumours harbour an EGFR-activating mutation](/index.php/en/component/content/article/58-english/safety-alerts-main/safety-alert-2016/1061-tarceva-erlotinib-first-line-maintenance-indication-now-restricted-to-treatment-of-patients-whose-tumours-harbour-an-egfr-activating-mutation.html?Itemid=1391) [Adempas\u00ae (Riociguat): New Contraindication Interstitial Pneumonias (PH-IIP)](/index.php/en/component/content/article/58-english/safety-alerts-main/safety-alert-2016/1056-adempas-riociguat-new-contraindication-for-patients-with-pulmonary-hypertension-associated-with-idiopathic-interstitial-pneumonias-ph-iip.html?Itemid=1391) [Direktif Untuk Melaksanakan Malaysian Variation Guideline for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products (Abridged ( Traditional Medicine & Homeopathy ) and Health 60mg (denosumab): Clinically Cases untuk menguatkuasakan penggunaan Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs), December 2015 dan G](/index.php/en/directive-general/100-directives-biologics/985-dasar-penguatkuasaan-regulatori-terhadap-produk-cell-gene-therapy.html) [Kenyataan [Arahan Cosmetic Manufacturer in Malaysia that conforms to the requirement of Good Manufacturing Practices (GMP) in accordance to the ASEAN Guideline for Cosmetic Good Manufacturing Practice](/index.php/en/component/content/article/36-english/announcement-main/announcement-2016/967-list-of-cosmetic-manufacturer-in-malaysia-that-conforms-to-the-requirement-of-good-manufacturing-practices-gmp-in-accordance-to-the-asean-guideline-for-cosmetic-good-manufacturing-practice.html?Itemid=1391) [Cellcept\u00ae (mycophenolate mofetil): Teratogenic risk - important new women and men](/index.php/en/component/content/article/32-english/safety-alerts-main/safety-alert-2015/970-cellcept-mycophenolate-mofetil-teratogenic-risk-important-new-pregnancy-prevention-advice-for-women-and-men.html?Itemid=1391) the ASEAN TMHS Scientific Committee (ATSC) and Related Meetings of the ACCSQ TMHS PWG Task Force](/index.php/en/component/content/article/52-english/announcement-main/announcement-2012/884-the-14th-meeting-of-the-asean-tmhs-scientific-committee-atsc-and-related-meetings-of-the-accsq-tmhs-pwg-task-force.html?Itemid=1391) [Ulasan Laporan Akhbar : A Pharmaceutical Company in India Recalled A Cholesterol-Lowering Drug Found Containing akhbar Sin Chew Daily - The Popular non-prescription drug from US and UK 'Alli' Weight Loss Capsule May Cause Consultative Committee for Standards and Quality - Pharmaceutical Product Working Group Meeting (First announcement. Further information will be provided shortly)](/index.php/en/component/content/article/43-english/announcement-main/announcement-2014/798-21st-asean-consultative-committee-for-standards-and-quality-pharmaceutical-product-working-group-meeting-first-announcement-further-information-will-be-provided-shortly.html?Itemid=1391) [Kenyataan Amaran Berkaitan Dengan 'Increased Risk For Opportunistic Infections Such As Activation of Latent Viral Infections Including BK Virus - Associated TM/HS Draft 1.3 and Presentation Slides for Training Course on Malaysian Variation Guideline for Traditional Medicine and Health Supplement Products](/index.php/en/component/content/article/43-english/announcement-main/announcement-2014/797-malaysian-variation-guideline-for-tm-hs-draft-1-3-and-presentation-slides-for-training-course-on-malaysian-variation-guideline-for-traditional-medicine-and-health-supplement-products.html?Itemid=1391) [Press Release on Animal Testing and Compliance to Good Laboratory Practice (GLP) of Organisation for Economic Co-operation and Development of cosmetic products which found to contain Scheduled Poison: Derma-RX Arbutin-R Cream](/index.php/en/component/content/article/47-english/press-release/press-release-2011/788-press-statement-of-cosmetic-products-which-have-been-found-to-contain-scheduled-poison-derma-rx-arbutin-r-cream.html?Itemid=1391) [Maklumbalas Akhbar : MYLOTARG\u00ae FOR LEUKEMIA FROM PFIZER RESULTED IN HIGH MORTALITY RATE. THE UNITED STATES BANNED ITS SALE IN THE MARKET](/index.php/en/component/content/article/46-english/press-release/press-release-2010/787-maklumbalas-akhbar-mylotarg-for-leukemia-from-pfizer-resulted-in-high-mortality-rate-the-united-states-banned-its-sale-in-the-market.html?Itemid=1391) [Membekal Dalam China Press 1 Februari 2013 Bertajuk : France Banned The Sale of Oral Contraceptive Pills Which Caused 4 Deaths](/index.php/en/component/content/article/42-english/press-release/press-release-2013/765-ulasan-kepada-laporan-dalam-china-press-1-februari-2013-bertajuk-france-banned-the-sale-of-oral-contraceptive-pills-which-caused-4-deaths.html?Itemid=1391) [Ulasan kepada laporan dalam China Sin Chew Daily (27 Februari 2013) : 3 Unregistered Health Supplement Product, Suspected from Malaysia & Indonesia](/index.php/en/component/content/article/42-english/press-release/press-release-2013/763-ulasan-kepada-laporan-dalam-china-sin-chew-daily-27-februari-2013-3-unregistered-health-supplement-product-suspected-from-malaysia-indonesia.html?Itemid=1391) [21st Asean Consultative Committee for Standards and Quality (ACCSQ); Pharmaceutical Product Working Group (PPWG)](/index.php/en/component/content/article/43-english/announcement-main/announcement-2014/760-21st-asean-consultative-committee-for-standards-and-quality-accsq-pharmaceutical-product-working-group-ppwg.html?Itemid=1391) [Ulasan Chew Daily Bertajuk \"Yin Ni Whitener Repair Cream Contains High Level of Mercury. Hong Kong Health Dept. Urged Consumers Not To Use It\"](/index.php/en/component/content/article/42-english/press-release/press-release-2013/758-ulasan-kepada-artikel-dalam-sin-chew-daily-bertajuk-yin-ni-whitener-repair-cream-contains-high-level-of-mercury-hong-kong-health-dept-urged-consumers-not-to-use-it.html?Itemid=1391) [Joint Press Release - MOH Malaysia & Standards Malaysia : The Acceptance of Malaysia as Non-OECD Member Adhering to the MAD In the Assessment of Chemicals on GLP](/index.php/en/component/content/article/42-english/press-release/press-release-2013/757-joint-press-release-moh-malaysia-standards-malaysia-the-acceptance-of-malaysia-as-non-oecd-member-adhering-to-the-mad-in-the-assessment-of-chemicals-on-glp.html?Itemid=1391) Bertajuk : Tong Ren Tang Jian Ti Wu Bu Wan Contains High Level of JULAI 2013 BERTAJUK : \" 2 WHITENING PRODUCTS CONTAIN MERCURY. THE AUTHORITY OF SINGAPORE URGED THE PUBLIC NOT TO USE THEM.\"](/index.php/en/component/content/article/42-english/press-release/press-release-2013/745-ulasan-kepada-laporan-dalam-kenyataan-akhbat-sin-chew-daily-bertarikh-10-julai-2013-bertajuk-2-whitening-products-contain-mercury-the-authority-of-singapore-urged-the-public-not-to-use-them.html?Itemid=1391) [ULASAN KEPADA HUANG JIE DU PIAN POISONOUS? TONG REN TANG: THE STANDARD OF DRUG USAGE & POLICY FOR WESTERN MEDICATIONS IS DIFFERENT FROM CHINESE 25-29 AUG, (denosumab): Updated recommendations to minimise the risk of severe symptomatic hypocalcaemia (SSH) and osteonecrosis of the jaw (ONJ)](/index.php/en/component/content/article/32-english/safety-alerts-main/safety-alert-2015/573-xgeva-120mg-solution-for-injection-denosumab-updated-recommendations-to-minimise-the-risk-of-severe-symptomatic-hypocalcaemia-ssh-and-osteonecrosis-of-the-jaw-onj.html?Itemid=1391) [Artrodar\u00ae50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects syndrome in patients with cancer (filgastrim & pegfilgastrim) syndrome in patients with cancer (filgastrim & pegfilgastrim) and Toxic Epidermal Necrolysis (TEN) have been reported in treated with Vectibix\u00ae](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/584-vectibix-panitumumab-rare-cases-of-stevens-johnson-syndrome-sjs-and-toxic-epidermal-necrolysis-ten-have-been-reported-in-patients-treated-with-vectibix.html?Itemid=1391) [Ritalin and Ritalin LA\u00ae (methylphenidate hydrochloride): New warning on patients for Attention Deficit Hyperactivity Disorder (ADHD)](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/581-ritalin-and-ritalin-la-methylphenidate-hydrochloride-new-warning-on-priapism-in-patients-treated-for-attention-deficit-hyperactivity-disorder-adhd-date-08-july-2014.html?Itemid=1391) [Risperidone and Paliperidone: Risk of Intraoperative Floppy Syndrome 2mg and Ethinylestradiol 0.035mg: Restriction of Indication and Measures to Reduce Risk of Thromboembolism](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/587-combination-products-containing-cyproterone-acetate-2mg-and-ethinylestradiol-0-035mg-restriction-of-indication-and-measures-to-reduce-risk-of-thromboembolism.html?Itemid=1391) [Tykerb\u00ae (Lapatinib): Comparative data have shown that lapatinib based regimens are less effective than trastuzumab based regimens metastatic breast cancer in certain settings](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/593-tykerb-lapatinib-comparative-data-have-shown-that-lapatinib-based-regimens-are-less-effective-than-trastuzumab-based-regimens-for-metastatic-breast-cancer-mbc-in-certain-settings.html?Itemid=1391) [Concerta\u00ae (Methylphenidate hydrochloride): New warning on priapism in Deficit Hyperactivity Disorder (ADHD)](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/592-concerta-methylphenidate-hydrochloride-new-warning-on-priapism-in-patients-treated-for-attention-deficit-hyperactivity-disorder-adhd.html?Itemid=1391) [Zofran\u00ae (Ondansetron): Dose-dependent QT interval prolongation - updated information on posology for intravenous (IV) use in the prevention of Chemotherapy-Induced Nausea And Vomiting (CINV)](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/591-zofran-ondansetron-dose-dependent-qt-interval-prolongation-updated-information-on-posology-for-intravenous-iv-use-in-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv.html?Itemid=1391) [Erbitux\u00ae (Cetuximab): Importance of establishing wild type RAS status (exons 2,3,4 of KRAS and NRAS) (mCRC)](/index.php/en/component/content/article/59-english/safety-alerts-main/safety-alert-2014/590-erbitux-cetuximab-importance-of-establishing-wild-type-ras-status-exons-2-3-4-of-kras-and-nras-before-treatment-in-metastatic-colorectal-cancer-mcrc.html?Itemid=1391) Tablet and paracetamol): mission is to safeguard the nation's health through scientific excellence in the regulatory control of medicinal products and cosmetics. COVID-19 PRODUCT SEARCH REPORTING OF SIDE EFFECTS TO MEDICINES OR VACCINES |03 Oct 2023;| "}